Edgewise shares rally after sale of muscular dystrophy unit to Servier
Edgewise Therapeutics stock jumped sharply in pre-market trading after the company agreed to sell its muscular dystrophy program, including sevasemten, to French drugmaker Servier for up to $2.65 billion. The transaction delivers $1.55 billion in upfront cash plus as much as $1.1 billion in milestone payments and was approved unanimously by both co…